4D Molecular Therapeutics Inc (FDMT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 4D Molecular Therapeutics Inc (FDMT) has a cash flow conversion efficiency ratio of 0.056x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($28.55 Million) by net assets ($505.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 4D Molecular Therapeutics Inc (FDMT) balance sheet quality index to measure how much of total assets are equity-financed.
4D Molecular Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how 4D Molecular Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of 4D Molecular Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
4D Molecular Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 4D Molecular Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Velesto Energy Bhd
KLSE:5243
|
0.016x |
|
Veradigm Inc.
NASDAQ:MDRX
|
0.024x |
|
Dap Gayrimenkul Gelistirme AS
IS:DAPGM
|
0.016x |
|
Dutch Lady Milk Industries Bhd
KLSE:3026
|
0.002x |
|
BTQ Technologies Corp.
NEO:BTQ
|
-0.343x |
|
Hainan RuiZe New Building Material Co Ltd
SHE:002596
|
-0.008x |
|
Luoyang Northglass Technology Co Ltd
SHE:002613
|
0.040x |
|
Pilani Investment and Industries Corporation Limited
NSE:PILANIINVS
|
0.038x |
Annual Cash Flow Conversion Efficiency for 4D Molecular Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of 4D Molecular Therapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see FDMT market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $505.66 Million | $-109.08 Million | -0.216x | +18.16% |
| 2024-12-31 | $510.61 Million | $-134.59 Million | -0.264x | -7.05% |
| 2023-12-31 | $307.83 Million | $-75.79 Million | -0.246x | +34.29% |
| 2022-12-31 | $231.34 Million | $-86.69 Million | -0.375x | -72.96% |
| 2021-12-31 | $319.11 Million | $-69.13 Million | -0.217x | -9.11% |
| 2020-12-31 | $256.39 Million | $-50.91 Million | -0.199x | -139.47% |
| 2019-12-31 | $-72.97 Million | $-36.71 Million | 0.503x | -14.60% |
| 2018-12-31 | $-27.59 Million | $-16.25 Million | 0.589x | +240.11% |
| 2017-12-31 | $-19.59 Million | $8.24 Million | -0.420x | -- |
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production o… Read more